CD274 and cancer: Following the discovery of the PD-1/PD-1-ligand 1 (PD-L1) pathway as an immunological target to control cancer, immune checkpoint inhibitors, including pembrolizumab, have been designed to overcome the inhibitory responses of cytotoxic T lymphocytes to promote antitumor immune responses [12,13,14].